CAT 2054

Drug Profile

CAT 2054

Alternative Names: CAT-2054; Eicosapentaenoic acid-niacin conjugate (CAT 2054); Niacin-eicosapentaenoic acid conjugate (CAT 2054)

Latest Information Update: 28 Jul 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Catabasis Pharmaceuticals
  • Class Antihyperlipidaemics; Eicosanoids; Nicotinic-acids; Omega 3 fatty acids; Peripheral vasodilators; Small molecules; Vitamins
  • Mechanism of Action Sterol regulatory element binding protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Hypercholesterolaemia

Most Recent Events

  • 30 Jun 2016 Catabasis completes its phase IIa trial for Hypercholesterolaemia in USA (NCT02608697)
  • 07 Jun 2016 Efficacy, adverse events and pharmacodynamics data from a phase IIa trial in Hypercholesterolaemia released by Catabasis Pharmaceuticals
  • 02 Mar 2016 Catabasis completes enrolment in its phase IIa trial for Hypercholesterolaemia in USA (NCT02608697)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top